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We previously identified structurally diverse small molecule (non-peptidic) inhibitors (SMNPIs) of the
botulinum neurotoxin serotype A (BoNT/A) light chain (LC). Of these, several (including antimalarial drugs)
contained a 4-amino-7-chloroquinoline (ACQ) substructure and a separate positive ionizable amine component.
The same antimalarials have also been found to interfere with BoNT/A translocation into neurons, via pH
elevation of the toxin-mediated endosome. Thus, this structural class of small molecules may serve as dual-
function BoNT/A inhibitors. In this study, we used a refined pharmacophore for BoNT/A LC inhibition to
identify four new, potent inhibitors of this structural class (IC50’s ranged from 3.2 to 17 íM). Molecular
docking indicated that the binding modes for the new SMNPIs are consistent with those of other inhibitors
that we have identified, further supporting our structure-based pharmacophore. Finally, structural motifs of
the new SMNPIs, as well as two structure-based derivatives, were examined for activity, providing valuable
information about pharmacophore component contributions to inhibition.
Introduction
Botulinum neurotoxins (BoNTs)a are the most potent of the
biological toxins; the lethal dose of BoNT serotype A (BoNT/
A) is estimated to be between 1 and 5 ng kg-1 for humans.1,2
As a result, these enzymes, which are responsible for the
paralysis associated with botulism, are listed as category A
(highest priority) biothreat agents by the Centers for Disease
Control and Prevention (CDC). BoNTs are easily produced and
may be delivered via food “spiking” and/or aerosol route.2-6
Furthermore, as BoNTs are now used to treat a range of medical
conditions, and in many cosmetic applications,3,7-14 they are
being produced in increasing quantities, making their misuse,
accidental overdosing, and/or instances of adverse side effects15
more likely. Neither the currently available CDC BoNT equine
antitoxins, which can cause adverse anaphylaxis and serum
sickness,16 nor experimental antibodies can counter these
enzymes once they are inside neurons. Furthermore, BoNT
intoxication can occur rapidly,17 and individuals who have been
maliciously exposed to a BoNT(s), or have received an
accidental overdose, will most likely seek medical attention only
after clinical symptoms (i.e., muscle paralysis) manifest. At this
time, critical care mechanical ventilation is the only life-saving
option once diaphragm muscles cease to function. Yet, the
effects of internalized BoNTs can last for weeks,18,19 rendering
such medical care impractical for wide scale application. By
comparison, small molecule (non-peptidic) inhibitors (SMNPIs)
could serve as post-intoxication “rescue” therapeutics and
prophylactics.
There are seven known BoNT serotypes (identified as A-F).
Each cleaves a component of the SNARE (soluble N-ethylma-
leimide-sensitive factor attachment protein receptor) com-
plex,20,21 which facilitates the transport of acetylcholine into
neuromuscular junctions. BoNT serotypes A and E cleave
SNAP-25 (synaptosomal-associated protein (25 kDa)),22 sero-
types B, D, F,23 and G cleave VAMP (vesicle-associated
membrane protein),24-27 and serotype C1 cleaves both SNAP-
25 and syntaxin 1.28
X-ray crystal structures of BoNT holotoxins29,30 show that
these enzymes are composed of a heavy chain (HC) and a light
chain (LC), which, following post-translational modification,
are connected by a disulfide bridge.29 The LC is a zinc
metalloprotease. The HC transports the LC into the neuronal
cytosol via an acidic endosome.
In a previous publication,31 we identified a range of novel,
structurally diverse, non-zinc chelating SMNPIs of the BoNT/A
LC. In particular, we showed that several compounds containing
the weakly basic (pKa  8) ACQ substructure and a separate
ionizable amine component were among the most potent of the
inhibitors.31 Additionally, we proposed binding modes for the
compounds and developed a common pharmacophore for
BoNT/A LC inhibition.31 In a subsequent molecular dynamics
study, we demonstrated that conformationally flexible loops
surrounding the BoNT/A LC substrate binding cleft may reorient
to decrease the solvent accessibility of the cleft (as compared
to respective energy refined structures), while simultaneously
providing more hydropathically feasible binding contacts for
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SMNPIs.32 The molecular dynamics studies were pivotal for
identifying a binding mode33 for the potent pseudo-peptide
inhibitor 2-mercapto-3-phenylpropionyl-RATKML (mpp-RAT-
KML, Ki ) 330 nM34). In the same study, we also proposed
new pharmacophore components and constraints based on the
docked model of mpp-RATKML, and, using this information,
we identified more potent SMNPIs.33 In this study, we build
on our previous work by describing how the refined pharma-
cophore33 was used to discover new small molecule inhibitors
possessing the ACQ substructure and a separate ionizable,
aliphatic amine component.
Results and Discussion
Based on the identification of N,N-bis(7-chloroquinolin-4-
yl)diamines and five antimalarial drugs (amodiaquine, chloro-
quine, quinacrine, quinidine, and quinine) as SMNPIs of the
BoNT/A LC,31 we have continued to pursue the identification
of new inhibitors of this structural class possessing the weakly
basic ACQ substructure and an ionizable amine; both of these
components have been found to be key to activity.31 Further
supporting this approach are the findings of Deshpande et al.35
and Sheridan et al.,36 demonstrating that ACQ-based drugs,
which also possess a separate ionizable nitrogen atom (e.g.,
amodiaquine), delay BoNT/A induced muscle paralysis. In those
studies, it was hypothesized that the compounds act by interfer-
ing with toxin translocation, most likely by increasing the pH
of the toxin-mediated endosome.35,36 This is a logical supposition
as ACQ antimalarials have been shown to target and increase
the pH of the acidic food vacuole of Plasmodium falciparum.37-39
However, neither of the earlier studies reported LC inhibition
in vitro. As indicated above, we demonstrated that several of
the same antimalarials also directly inhibit BoNT/A LC met-
alloprotease activity;31 however, they do so at higher concentra-
tions than reported in the muscle twitch assays used in the earlier
studies.35,36 This comparison indicates that the observed muscle
twitch inhibition could not have resulted solely from inhibition
of the enzyme’s LC. Thus, the Deshpande et al.35 and Sheridan
et al.36 data, in combination with our previous findings, indicate
that such molecules may serve as dual-function countermeasures,
acting both as translocation inhibitors and directly against the
metalloprotease activity of the LC.
A Refined Pharmacophore Is Used To Identify New
BoNT/A LC Inhibitors Possessing Both the ACQ Substruc-
ture and a Separate Ionizable Amine. The first step in
identifying new SMNPIs was to use a recently refined/expanded
pharmacophore for BoNT/A LC inhibition33 (Figure 1A) to
evaluate diverse target compounds possessing the ACQ sub-
structure. It is important to note that the eight-component
pharmacophore model presented in Figure 1A is a logical
extension of the six-component model shown in our original
work31 and is part of an ongoing refinement of our pharma-
cophore for BoNT/A LC inhibition32,33 (which is occurring as
more data become available). In this study, we wanted to identify
compounds containing as many pharmacophore features as
possible, but with the following specific components: (1) the
ACQ substructure (which incorporates pharmacophore compo-
nents A, a heteroatom associated with A, and C (Figure 1A)),
(2) an ionizable amine located 6.5-9.5 Å from the centroid of
the ACQ (pharmacophore component E (Figure 1A)), and (3)
at least one of the new components from our expanded
pharmacophore, either F33 (a positive ionizable moiety located
11.7-16.7 Å from the quinoline centroid) or G33 (a hydrophobic
moiety located 8.5-12.5 Å from the quinoline centroid) (Figure
1A). Subsequently, a congeneric series of 4-amino-7-chloro-
quinoline-cholate-acetates, 1-3, and a tri-ACQ derivative, 4,
were identified (see Scheme 1 for two-dimensional (2-D)
structures of 1-3 and Figure 2 for the 2-D structure of 4).
Pharmacophore mapping to 1-4 indicated that in each case
ACQ is plane A (Figure 1B-E), and the quinoline ring nitrogen
is the heteroatom associated with this plane. For 1-3, compo-
nent B is the central decahydronapthalene of the methyl cholate
acetate (rings B and C according to steroid ring designation)
(Figure 1B-D), while in 4 it is a second ACQ (Figure 1E).
Hydrophobic component C is the 7-chloro substituent of the
plane A ACQ for all inhibitors (Figure 1B-E), and pharma-
cophore component D is a methyl for 1 (Figure 1B), an acetyl
group for 2 and 3 (Figure 1C and D), and a chloro substituent
for 4 (Figure 1E).
As a second specific criterion, each of the molecules contains
a separate ionizable, aliphatic amine (Figure 1B-E), which
corresponds to pharmacophore component E (Figure 1A).
Finally, all of the molecules possess hydrophobic pharmacoph-
ore component G from the expanded/refined pharmacophore33
(Figure 1A) (the third specified criterion, see above), which is
an acetyl group for 1 and 2 (Figure 1B and C), a methyl group
for 3 (Figure 1D), and a chloro substituent for 4 (Figure 1E).
Figure 1. Pharmacophore mapping to inhibitors 1-4. (A) The refined/
expanded pharmacophore for BoNT/A LC inhibition. Planar compo-
nents A and B are magenta rectangles. The dashed, green circle in plane
A represents a heteroatom. Hydrophobic components C and D are
shown as dashed, light blue circles. The positive ionizable pharma-
cophore component E is shown as a dashed, red circle. New pharma-
cophore component F,33 also a positive ionizable moiety, is shown as
a dashed red circle, while new hydrophobic pharmacophore component
G is a dashed orange circle. (B, C, D, and E) Mapping of inhibitors
1-4, respectively, to the expanded pharmacophore. Distances between
components are in angstroms. Pharmacophore component colors are
as indicated in (A).
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As observed in Figure 1B-E, 1-4 all show a good fit with
respect to the distance constraints specified by the pharmacoph-
ore.
In Vitro Testing. Compounds 1-3 were initially examined
for percent inhibition of the BoNT/A LC at 50 íM concentra-
tions, while 4 was tested at a 20 íM concentration. Results from
these initial analyses indicated 90% enzyme inhibition by 1 and
3, 80% inhibition by 2, and 67% inhibition by 4. Subsequent
determination of IC50 values revealed that SMNPIs 1-4 are
among the most potent inhibitors of the BoNT/A LC reported
to date,33,40-42 possessing IC50 values ranging from 3.2 to 17.0
íM (Table 1). In agreement with structurally distinct SMNPIs
reported by our research group (possessing Ki values ranging
from 3.0 to 10.0 íM33), compounds 1-4 demonstrate that our
strategy of incorporating new pharmacophore features (i.e.,
pharmacophore components F or G),33 in addition to original
components,31,32 results in the identification of more potent
inhibitors.
Molecular Docking of SMNPIs 1-4 Demonstrates a
Consistency with Previous Inhibitor Binding Modes, Rein-
forcing Our Structure-Based Pharmacophore Approach.
Compounds 1-4 were docked in the BoNT/A LC substrate
binding cleft to determine if they would also engage in
intermolecular contacts that were comparable to those predicted
for other structurally diverse SMNPIs.31-33 Similar to our
previously docked models of ACQ inhibitors,31,32 the 7-chloro
Scheme 1a
a Reagents and conditions: (a) (i) MsCl, pyridine; (ii) 6, DMF; (b) 6, NaBH3CN, CH3CN; (c) allyl bromide, iPr2NEt, NMP, 80 °C; (d) (i) O3, MeOH, -78
°C; (ii) Me2S; (e) 6, NaBH(OAc)3, CH2Cl2; (f) NaBH(OAc)3, CH2Cl2; (g) (i) MsCl, pyridine; (ii) NaN3, DMF; (h) PPh3, THF, H2O, 50 °C; (i) 4,7-
dichloroquinoline, PhOH, 120 °C.
Figure 2. Two-dimensional structures of 4-9.
Table 1. Inhibitory Potencies of 1-4
SMNPI IC50a (íM)
1 10 ((0.80)
2 17 ((1.7)
3 7.0 ((1.0)
4 3.2 ((0.92)
a IC50 values for the SMNPIs were calculated from plots of concentration
versus inhibition (see Experimental Section for details). Results are the
averages of duplicate determinations.
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substituents of 1-3 (Figure 3A-C) and one of the ACQs of 4
(Figure 4A and B) engage in favorable hydrophobic contacts
with residues Phe 162, Phe 163, and Thr 219 of hydrophobic
binding subsite 131-33 (also described as the S1′ binding site34).
At the same time, the quinoline nitrogens of the inhibitors are
positioned so that this heteroatom may interfere with the
enzyme’s catalytic engine. This same heteroatom:catalytic
engine perturbation has been a consistent theme in the docked
models of described SMNPIs, including those in which phar-
macophore plane A is an indolyl/benzofuranyl,31-33 as well as
those possessing the ACQ substructure.31
Linker methylenes of 1-4 engage in favorable hydrophobic
collapse with the side chain methylenes of Lys 65, and the
hydrophobic side chains of Val 67 and Pro 68 (Figure 3A-C;
Figure 4A and B). These residues are part of a flexible loop
(LC residues 48-78, referred to as loop 1 for the remainder of
the text) that reorients toward the enzyme’s substrate binding
cleft during molecular dynamics analysis.32,33 As in our previous
reports,32,33 this loop reorientation, in addition to providing
favorable new inhibitor contacts, also provides solvent shielding
for SMNPIs. This is clearly observed in Figure 3A-C and
Figure 4A and B, as loop 1 residues are located directly above
atoms linking the ACQ and cholate-acetate components of 1-3,
and two of the ACQs of 4.
The secondary nitrogens of 1-3, and the tertiary nitrogen of
4, engage in hydrogen bonds with the side chain carboxylate
of Glu 63, a residue located in a polar contact region of the
substrate binding cleft (Figure 3A-C; Figure 4A and B).31-33
This intermolecular hydrogen bond is also consistent with our
docked model of mpp-RATKML,33 in which the Arg side chain
guanidinium is predicted to engage in a hydrogen bond with
the Glu 163 side chain carboxylate.
The steroidal components of 1-3, in addition to occupying
a significant volume of the LC substrate cleft, also serve as
rigid platforms for positioning key pharmacophore components
in binding subsite 2.31-33 For SMNPI 1, the C20 methyl group
occupies steric space in the substrate cleft that is located directly
behind His 226 and adjacent to Cys 164 (Figure 3A). For
inhibitors 2 and 3, this same space is occupied by 7R-acetyl
(Figure 3B) and 12R-acetyl (Figure 3C) substituents, respec-
tively, while a second chloro substituent from SMNPI 4 occupies
this space (Figure 4A and B). In each case, the binding modes
of the methyl, acetyl, and chloro substituents are consistent with
similar cleft occupancy observed for hydrophobic chloro,
methyl, and methoxy substituents in the docked models of other,
structurally diverse, SMNPIs.31-33
The 7R- and 12R-acetyl substituents of SMNPIs 1 and 2,
respectively, pack behind Pro 238 (Figure 3A and B), while
the same steric space is occupied by the C13 methyl group of
3 (Figure 3C), and a third ACQ of SMNPI 4 (Figure 4A and
B). Moreover, two potential binding modes were identified for
SMNPI 4. Specifically, we found that intramolecular ð stacking
between two of the three ACQ quinoline rings reinforces the
stability of the predicted binding modes by significantly
Figure 3. Docked models of SMNPIs 1-3. Inhibitors are depicted in thicker stick with white carbons. Carbons of binding subsite 1 residues are
cyan, of binding subsite 2 are magenta, and of the polar contact region are orange. All other carbons are green. Oxygen atoms are red, and nitrogen
atoms are blue. The yellow dashed line indicates a hydrogen bond. (A, B, and C) Docked models of SMNPIs 1, 2, and 3, respectively.
Figure 4. ð stacking by two of the quinoline rings of SMNPI 4 results in two feasible binding modes. Colors, stick thicknesses, and dashed lines
are as indicated in Figure 3. (A) The inhibitor docked with the chloro substituents of the ð stacking quinoline rings facing into the substrate binding
cleft. (B) An alternative binding mode with one of the ð stacking quinolines oriented in the opposite direction.
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decreasing the conformational freedom of the inhibitor. In the
first binding mode (Figure 4A), hydrophobic packing near Pro
238 is achieved with the ACQ chloro substituent oriented into
the substrate cleft, while in the second binding mode (Figure
4B) it is achieved with the chloro substituent facing the opposite
direction.
For SMNPIs 1-4, favorable hydrophobic interactions with
the Pro 238 side chain are consistent with those observed for
the Met residue of the docked model of mpp-RATKML.33
Indeed, the hydrophobic contacts between the mpp-RATKML
Met and the side chain of Pro 238 were used to derive
component G of the refined/expanded pharmacophore (Figure
1A).33 Of significance to this study is the observation that the
predicted binding modes of 1-4 indicate that the G component
adds an additional hydrophobic anchor and, in doing so, results
in improved substrate cleft complementarity.
Inhibitors 1-3 also resemble the docked model of mpp-
RATKML in that the 3R-acetyl substituent of 1 and the C23
substituents of both 2 and 3 all dock so that a methyl moiety
points toward and engages in favorable contacts with the side
chain of Val 171, which is located in flexible loop 2 (residues
167-180) at the lower edge of the binding cleft (with respect
to the orientation of the enzyme in Figure 3A-C). However, it
is important to note that, while pharmacophore components of
the SMNPIs share similar binding site contacts with corre-
sponding components of mpp-RATKML, the unique, optimized
steric occupancy achieved by the pseudo-peptide,34 as compared
to the identified SMNPIs, is reflected in the fact that it is still
the most potent inhibitor of the BoNT/A LC reported to date.33
Unfortunately, our ability to completely take advantage of this
novel steric space is limited. This is due to a lack of steric
congruency between the way in which the optimized pseudo-
peptide inhibitor34 populates the BoNT/A LC substrate binding
cleft and the positions on the SMNPIs where substituents can
be added or modified.
Finally, inhibitor 4 also occupies additional steric volume in
the substrate binding cleft (as compared to previously identified
SMNPIs31); in both of its proposed binding modes (Figure 4A
and B), one of the inhibitor’s ACQ’s packs behind His 169
(which is a residue of loop 2 that sits adjacent to Val 171 in the
three-dimensional structure of the enzyme).
The Effects of Inhibitor Structural Motifs and Derivatives
on BoNT/A LC Metalloprotease Activity: Pharmacophore
Component E Dominates Potency for This Structural Class.
The final analyses of this study involved determining the
importance of the structural components of 1-4 to BoNT/A
LC inhibition. To start, ACQ (4-amino-7-chloroquinoline, 5,
Figure 2), the smallest substructure common to the SMNPIs,
possessing pharmacophore component A, a heteroatom associ-
ated with this plane, and component C (Figure 1A), was
evaluated. The rationale for examining 5 was to determine if
two or more ACQs might simultaneously bind in the substrate
cleft, similar to the docked model of inhibitor 4 (but without
the need for a central linker). However, examination of this
substructure in our assay resulted in only 12% inhibition at a
concentration of 50 íM (Table 2). Hence, while ACQ is a key
component of molecules in this inhibitor class, it must be
coupled with additional pharmacophoric features to achieve
appreciable potency.
The above results prompted a question: would incorporating
atoms of the flexible linkers of 1-4, along with pharmacophore
component E, increase the potency of ACQ? Again, the smallest
structural denominators of the inhibitors were examined. For
1-3, the substructure was N1-(7-chloroquinolin-4-yl)-ethane-
1,2-diamine (6, Figure 2), which was found to inhibit the
BoNT/A LC by 33% at 50 íM concentration (Table 2); for 4,
the substructure was N1-(7-chloroquinolin-4-yl)-propane-1,3-
diamine (7, Figure 2), which inhibited the enzyme by 22% at
50 íM concentration (Table 2). On the basis of our docked
models, we hypothesize that the increase in activity for 6 and
7 (over that of 5) results from a hydrogen bond with an acidic
residue in the polar contact region (presumably Glu 63).
Moreover, our models also predict that the side chain methylenes
of 6 and 7 may desolvate under hydrophobic residues of loop
1, with the slightly lower potency of 7 most likely resulting
from a higher entropic binding penalty.
Focus was next placed on the methyl cholate acetate
component (8, Figure 2) of SMNPIs 1-3, which incorporates
pharmacophoric features B, C, and G (Figure 1B-D). Because
of its rigidity and bulk, it was hypothesized that 8 alone might
demonstrate a moderate degree of inhibition; however, when
examined at a 50 íM concentration against the BoNT/A LC, it
was inactive (Table 2). Thus, the steroidal motif alone cannot
effectively populate the enzyme’s substrate binding cleft in the
absence of the ACQ and/or ionizable amine moieties. To
determine if incorporating pharmacophore component E might
transform 8 into an inhibitor, the 3R-acetyloxy group of this
molecule was replaced with an ionizable 3R-NH2 substituent
(9, Figure 2), effectively creating a substructure of SMNPI 3
(Scheme 1), the most potent molecule of the ACQ-cholate
acetate congener series (Table 1). Examination of 9 in the in
vitro assay revealed that this was the case, as this substructure
provided 13% enzyme inhibition at a 50 íM concentration
(Table 2). These data both underscore the importance of an
ionizable, aliphatic amine to the potency of this class of
inhibitors, as well as the need for the ACQ component.
To further probe the requirements of pharmacophore com-
ponent E, a new derivative of SMNPI 3 (Scheme 1) possessing
a non-ionizable oxygen atom at the 3R position of the cholate-
acetate was generated. Designated 10 (Scheme 1), this molecule
was designed to determine if an ether oxygen might also suffice
at this key position. For example, it was hypothesized that a
water molecule might bridge a hydrogen bond between the Glu
63 side chain carboxylate and the ether oxygen of 10. Interest-
ingly, examination of 10 at 50 íM concentration resulted in
only 9% enzyme inhibition (Table 2), providing additional
evidence that the ionizable, aliphatic amine found in SMNPIs
1-4 is interacting with an unprotonated acidic residue, as
predicted by our molecular models (Figures 3 and 4).
Finally, to determine if it would be possible to restore the
inhibitory potency of 10, the 3R-O-cholate-acetate and ACQ
components were tethered with an extended linker incorporating
a central, secondary amine. Gratifying, the resulting derivative,
11 (Scheme 1), was found to inhibit the BoNT/A LC by 62%
at a 50 íM concentration (Table 2). In a docked model of 11
(Figure 5), the secondary amine in the extended linker engages
in a hydrogen bond with the side chain carboxylate of Glu 63,
Table 2. Inhibitory Potencies of 5-11
compound
% inhibitiona
(50 íM)
5 12
6 33
7 22
8 0
9 13
10 9
11 62
a Percent inhibition measurements were performed in duplicate, and in
all cases standard deviations were less than (25%.
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in a manner similar to that of the secondary amine found in the
linker of SMNPI 1 (Figure 3A). Furthermore, the extended tether
also orients the 3R-oxygen atom of 11 toward the stern layer,
eliminating the possibility of unfavorable contacts with polar
enzyme residues (Figure 5). However, due to the increased
length of the SMNPI, the cholate-acetate portion of 11 cannot
attain the same depth of binding as that of 1-3, thus rational-
izing its reduced activity (for comparison, 3 inhibits the BoNT/A
LC by 90% at 50 íM concentration). Specifically, the extended
linker forces the cholate-acetate portion of 11 to adopt a
shallower binding mode, with its C23 methoxycarbonyl oriented
outside of the substrate binding cleft (Figure 5). In addition,
while the SMNPI’s 12R-acetyl group faces binding subsite 2,
it does so in a sterically shallow location in the substrate cleft
that is adjacent to flexible loop 2 (Figure 5). For comparison,
the 12R-acetyl substituent of 3 binds in a deeper location in
subsite 2 that is directly behind catalytic engine residue His
226 (Figure 3C). However, it is noteworthy that the C10 methyl
of 11 does adopt a binding site location that occupies the steric
space behind Pro 238, as also observed for substituents
comprising pharmacophore component G in SMNPIs 1-3.
Based on the examination of substructures 5-9 and deriva-
tives 10 and 11, the importance of pharmacophore component
E to the potencies of SMNPIs in this structural class is evident.
Indeed, Table 2 shows that each time this pharmacophoric
feature is added, the potency of its derivative increases
substantially, in one of the most extreme cases, compound 10
versus SMNPI 11, by nearly 7-fold. Additionally, replacement
of the aliphatic amine in SMNPI 3 with a polar, non-ionizable
oxygen isostere results in an inhibitor that is 10-fold less active.
Interestingly, even as pharmacophore component E is key to
BoNT/A LC inhibition, it is also central to the hypothesis that
these molecules may act as BoNT translocation inhibitors, as
the ionizable, aliphatic amine would be responsible for elevating
the pH of the toxin-induced endosome. Indeed, we hypothesize
that alkalinization of the endosome by the ionizable amine
component of the ACQs will potentially result in the trapping
and accumulation of these small molecules in the acidic
compartment; hence, the in vivo efficacies of the ACQ-based
inhibitors may be even more pronounced than anticipated from
in vitro studies.
Chemistry. The syntheses of SMNPIs 1-4, and derivatives
10 and 11, have not been reported. Because of the process
whereby 1-4 were identified as BoNT/A LC inhibitors,
presenting their syntheses at the beginning of the Results and
Discussion would not follow the scientific evolution of this
study. Therefore, descriptions of the syntheses of the inhibitors
and derivatives are provided at a non-traditional, but more
logical, location in the text.
Targets 1, 2, 3, and 11 were obtained by amination reactions
of corresponding precursors with 6 (Scheme 1). The key
aldehyde 15 was obtained from alcohol 13, which was allylated
and subsequently ozonized (Scheme 1). Amino ether 11 (43%
from 14) was obtained in a reductive amination reaction between
6 and aldehyde 15 (Scheme 1). Alternatively, ketone 19
(obtained from 13)43 underwent amination with 6 to afford
quinoline epimers 2 and 3 (Scheme 1) in a ratio of 1.3:1.
Interestingly, although the reactive intermediate is an imine
(iminium cation, sp2 C3), the reductive amination of the cholic
acid derivative (5â-series) afforded epimeric 2 and 3 in
comparable amounts, unlike the reductions of 5â-3-ketones
affording almost exclusively equatorial 3R-epimer.44 Azide 17,
obtained from alcohol 16, was transformed into amine 18 and
coupled to 4,7-dichloroquinoline, affording compound 10
(Scheme 1). Finally, quinolines 6 and 745 and trisquinoline 4
(33%) were obtained according to a well-established procedure43
using the corresponding di- and triamines and 4,7-dichloro-
quinoline.
Conclusion
An expanded/refined pharmacophore for BoNT/A LC inhibi-
tion33 was used to identify four new, potent SMNPIs of the ACQ
structural class. In each case, docking of the inhibitors dem-
onstrated that they follow a consistent structure-based theme,
engaging in intermolecular substrate binding cleft contacts
modeled for other SMNPIs.31-33 However, unlike any other
BoNT/A LC inhibitors that we have identified to date,31,33
SMNPIs 1-4 and 11 incorporate a new pharmacophore
component G, which is predicted to serve as a hydrophobic
anchor at the edge of the substrate binding cleft, resulting in
greater cleft complementarity and occupancy. This provides
additional support that molecular scaffolds, which are larger
than many reported BoNT/A LC inhibitors,31,40-42 are needed
to provide superior inhibition. Finally, examination of substruc-
tures composing 1-4 (i.e., compounds 5-9), as well as
derivatives 10 and 11, revealed the critical importance of
positive-ionizable pharmacophore component E to the potencies
of inhibitors in the structural class. This information will be
central to the structure-based design of future ACQ-based
inhibitors of the BoNT/A LC.
Experimental Section
Chemistry. General Considerations. Melting points were
determined on a Boetius PMHK or a Mel-Temp apparatus and were
not corrected. Optical rotations were measured on a Rudolph
Research Analytical automatic polarimeter, Autopol IV. IR spectra
were recorded on a Perkin-Elmer spectrophotometer FT-IR 1725X.
NMR spectra were recorded on Varian Gemini-200, Varian XL-
300, and Bruker AM-250 spectrometers in the indicated solvent
using TMS as internal standard. EI and CI mass spectra were
recorded on a MS Finnigan-MAT 8230 spectrometer with double
focusing reverse geometry, using isobutane (CI). Microanalyses
were performed by M-H-W Laboratories, Phoenix, AZ. Thin-layer
chromatography (TLC) was performed on precoated Merck silica
gel 60 F254 and RP-18 F254 plates. For column chromatography,
Lobar LichroPrep Si 60 (40-63 ím) and RP-18 (40-63 ím)
columns coupled to a Waters RI 401 detector were used.
4-Amino-7-chloroquinoline (5), N1-(7-chloroquinolin-4-yl)-
ethane-1,2-diamine (6), N1-(7-chloroquinolin-4-yl)-propane-1,3-
Figure 5. SMNPI 11 docked in the BoNT/A LC substrate binding
cleft. All colors, stick thicknesses, and the dashed line are as indicated
in Figure 3. As compared to SMNPIs 1-3, the cholate-acetate portion
of the inhibitor adopts a shallower binding mode as a result of increasing
the length of the flexible tether between the ACQ and cholate-acetate
components.
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diamine (7), and methyl 3R-amino-7R,12R-diacetoxycholan-24-oate
(9) were prepared according to known procedures.45-49 Methyl
cholate triacetate (8) was purchased form Aldrich and used as
obtained.
N-(3r,7r,12r-Triacetoxy-5â-cholan-24-yl)-N′-(7′-chloroquin-
olin-4′-yl)-ethane-1,2-diamine (1). Methanesulfonyl chloride (84.9
íL, 1.09 mmol) was added to an ice-cold solution of 3R,7R,12R-
diacetoxy-5â-cholan-24-ol50 (12) (Scheme 1) (381.9 mg, 0.73
mmol) in dry pyridine (10 mL), and the resulting mixture was stirred
at 0 °C for 1 h. Diethyl-ether (30 mL) was added, and the organic
layer was washed with diluted HCl (1/1), followed by sat. NaHCO3
(2  15 mL) and brine, and dried over anhydrous Na2SO4. The
solvent was removed under reduced pressure, leaving the crude
mesylate (411.7 mg; 94%). In the next step, the crude mesylate
and 6 (305.9 mg, 1.38 mmol) were stirred overnight at 60 °C in
dry DMF (4 mL) and evaporated to dryness. The resulting solid
was purified on a SiO2 column (dry-flesh, AcOEt (8  10 mL),
AcOEt/MeOH/NH3 ) 9/1/1 (14  10 mL)). Fractions were
combined, evaporated to dryness, suspended in CH2Cl2, and
undissolved 6 was removed by filtration. The dichloromethane
extract was evaporated to dryness and purified by column chro-
matography (Lobar Lichroprep B, eluent MeOH/H2O ) 98/2, Lobar
B Lichroprep RP, eluent MeOH/H2O ) 9/1, and Lobar A
Lichroprep RP-18, eluent MeOH/H2O ) 85/15) to afford 1 (104
mg (24%)). Colorless foam softness at 95-98 °C. [R]20D ) +30.0
(c ) 1.0, CH2Cl2). IR (KBr): 3405m, 2943s, 2875m, 1736s, 1618w,
1584s, 1540w, 1452m, 1378s, 1334w, 1250s, 1143w, 1068w,
1030m, 970w, 941w, 887w, 853w, 814w, 774w, 735w, 647w,
617w, 588w cm-1. 1H NMR (200 MHz, CDCl3): ä 8.49 (d, J )
5.3, H-C(2′)), 7.93 (d, J ) 2.0, H-C(8′)), 7.75 (d, J ) 9.0,
H-C(5′)), 7.4-7.3 (m, H-C(6′)), 6.36 (d, J ) 5.3, H-C(3′)), 6.05
(bs, H-N), 5.09 (bs, H-C(12)), 4.95-4.85 (m, H-C(7)), 4.60-
4.50 (m, H-C(3)), 3.40-3.30 (m, 2H-C(9′)), 3.10-2.95 (m, 2H-
C(10′)), 2.70-2.50 (m, H-N), 2.40-2.20 (m, 2H-C(24)), 2.12
(s, CH3COO-), 2.08 (s, CH3COO-), 2.05 (s, CH3COO-), 0.91
(s, H3C-C(10)), 0.82 ((d, J ) 6.2, H3C-C(20)), 0.71 (s, H3C-
C(13)). 13C NMR (50 Hz, CDCl3): ä 170.53, 170.37, 151.87,
149.92, 148.88, 134.70, 128.34, 125.07, 121.44, 117.28, 98.99,
75.32, 73.98, 70.61, 49.67, 47.54, 47.40, 44.90, 43.26, 41.92, 40.77,
37.58, 34.83, 34.52, 34.18, 33.18, 31.10, 28.77, 27.18, 26.73, 26.53,
25.44, 22.65, 22.42, 21.50, 21.38, 21.30, 17.77, 12.09. MS-CI (m/z
(%)): 725 [(M + H)+, (100)], 667 (10), 223 (100), 193 (25).
Methyl 3â-(N-[(7-Chloroquinolin-4-yl)amino]ethyl}amino),7r,-
12r-diacetoxy-5â-cholan-24-oate (2) and Methyl 3r-(N-[(7-
Chloroquinolin-4-yl)amino]ethyl}amino),7r,12r-diacetoxy-5â-
cholan-24-oate (3). Methyl 7R,12R-diacetoxy-3-oxo-5â-cholan-24-
oate51 (19) (Scheme 1) (504 mg, 1.0 mmol) and 6 (1.7 g, 7.7 mmol)
was dissolved in a CH3CN/MeOH (2/1, 15 mL) mixture, and
NaBH3CN (77.3 mg, 1.23 mmol) was added in one portion. The
resulting mixture was stirred for 2 h at room temperature, followed
by the addition of glacial AcOH (5 drops). The stirring was
continued until TLC indicated the consumption of all starting
ketone, ca. 1 h. The solvent was removed under reduced pressure,
and the obtained solid was triturated with CH2Cl2 (3  40 mL).
The dichloromethane extracts were combined, the solvent was
removed, and the products were separated by column chromatog-
raphy (Lobar B Lichroprep RP-18, eluent MeOH/H2O ) 9/1) to
afford 2 and 3.
2: Yield 240.8 mg (34%). Colorless foam softens at 212-215
°C. [R]20D ) +35.0 (c ) 1.0 g, CH2Cl2). IR (KBr): 3331m, 3243m,
2938s, 2875m, 1731s, 1618m, 1594s, 1530m, 1471m, 1451m,
1378s, 1333m, 1250s, 1172m, 1142w, 1108w, 1029m, 961w, 931w,
887w, 853w, 809m, 765w, 730w, 608w, 509w cm-1. 1H NMR (200
MHz, CDCl3): ä 8.52 (d, J ) 5.6, H-C(2′)), 7.95 (d, J ) 2.0,
H-C(8′)), 7.67 (d, J ) 9.0, H-C(5′)), 7.4-7.3 (m, H-C(6′)), 6.38
(d, J ) 5.2, H-C(3′)), 6.0 (bs, H-N, exchangeable with D2O),
5.10 (bs, H-C(12)), 4.95-4.85 (m, H-C(7)), 3.66 (s, CH3O2C),
3.40-3.20 (m, H-C(9′)), 3.00-2.90 (m, H-C(10′), HR-C(3)), 2.12
(s, CH3COO-), 2.08 (s, CH3COO-), 0.96 (s, H3C-C(10)), 0.82
(d, J ) 6.0, H3C-C(20)), 0.74 (s, H3C-C(13)). 13C NMR (50 Hz,
CDCl3): ä 174.57, 170.49, 170.42, 152.14, 149.85, 149.12, 134.75,
128.78, 125.20, 121.04, 117.35, 99.23, 95.75, 75.47, 71.01, 52.04,
51.49, 47.30, 44.99, 44.81, 43.32, 42.33, 37.67, 36.16, 34.90, 34.56,
33.54, 31.12, 30.83, 30.70, 30.02, 28.28, 27.13, 25.64, 24.93, 23.25,
22.74, 21.58, 21.30, 17.44, 12.15. MS-CI (m/z (%)): 712 [(M +
2)+, (100)], 224 (80), 193 (40).
3: Yield 181.5 mg (26%). Colorless foam softens at 91-95 °C.
[R]20D ) +49.0 (c ) 1.0, CH2Cl2). IR (KBr): 3410m, 2943m,
2870m, 1736s, 1618w, 1589s, 1540w, 1452m, 1378m, 1334w,
1250s, 1200w, 1172w, 1142w, 1084w, 1030m, 971w, 941w, 888w,
853w, 814w, 770w, 647w, 613w, 559w, 509w, 480w, 455w cm-1.
1H NMR (200 MHz, CDCl3): ä 8.46 (d, J ) 5.4, H-C(2′)), 7.90
(d, J ) 2.0, H-C(8′)), 7.71 (d, J ) 9.0, H-C(5′)), 7.32 (dd, J )
2.2, J ) 9.0, H-C(6′)), 6.34 (d, J ) 5.6, H-C(3′)), 6.12 (bs, H-N,
exchangeable with D2O), 5.08 (bs, H-C(12)), 4.95-4.85 (m,
H-C(7)), 3.66 (s, CH3O2C), 3.45-3.35 (m, H-C(9′)), 3.10-3.00
(m, H-C(10′)), 2.92 (bs, H-N, exchangeable with D2O), 2.43 (m,
Hâ-C(3)), 2.08 (s, CH3COO-), 2.03 (s, CH3COO-), 0.92 (s,
H3C-C(10)), 0.81 (d, J ) 6.0, H3C-C(20)), 0.73 (s, H3C-C(13)).
13C NMR (50 Hz, CDCl3): ä 174.57, 170.66, 170.51, 151.74,
149.92, 148.77, 134.94, 128.37, 125.27, 121.41, 117.26, 99.01,
75.43, 70.83, 57.97, 51.51, 47.27, 44.99, 44.48, 43.32, 42.35, 41.48,
37.67, 36.42, 35.30, 34.72, 34.52, 31.37, 30.79, 30.66, 28.90, 28.02,
27.09, 25.47, 22.74, 21.60, 21.36, 17.41, 12.13. MS-EI (m/z (%)):
711 [M + H)+, (30)], 668 (25), 459 (30), 192 (100).
Tris[3-(7-chloroquinolin-4-yl)aminopropyl]amine (4). Fol-
lowing the procedure of Vennerstrom et al.,43 a solution of 4,7-
dichloroquinoline (2.97 g, 15 mmol), triethylamine (1.52 g, 15
mmol), and tris-(3-aminopropyl)amine (0.94 g, 5 mmol) in N-
methylpyrrolidinone (NMP, 10 mL) was subject to 10 purge-cycles
using a Firestone valve and then heated to reflux for 7 h under a
slight positive N2 pressure. After the reaction mixture cooled to
room temperature, ether (50 mL) and water (50 mL) were added
with stirring. After the mixture was cooled in the refrigerator, a
tan solid was filtered and washed with water and ethyl acetate to
provide, after crystallization from methanol, 4 (1.12 g, 33%). mp
198-200 °C; 1H NMR (300 MHz, DMSO-d6): ä 1.71-2.01 (m,
6H), 2.42-2.75 (m, 6H), 3.24 (d, J ) 4.8 Hz, 6H), 6.33 (d, J )
5.5 Hz, 3H), 7.28 (br s, 3H), 7.40 (dd, J ) 8.9, 1.9 Hz, 3H), 7.77
(d, J ) 2.0 Hz, 3H), 8.22 (d, J ) 9.1 Hz, 3H), 8.31 (d, J ) 5.3 Hz,
3H). 13C NMR (75 MHz, DMSO-d6): ä 25.35, 34.82, 40.84, 51.25,
98.50, 117.40, 123.94, 127.47, 133.29, 149.01, 150.01, 151.79.
Methyl 3r-(N-[(7-Chloroquinolin-4-yl)amino]ethyl})oxy,7r,-
12r-diacetoxy-5â-cholan-24-oate (10). A mixture of primary
amine 18 (Scheme 1) (87 mg, 0.16 mmol), 4,7-dichloroquinoline
(95 mg, 0.48 mmol), and phenol (223 mg, 2.32 mmol) was stirred
for 24 h at 120 °C. Upon cooling, the mixture was dissolved in
CH2Cl2 and washed with dilute NaOH (6  20 mL) and brine, and
dried over anhydrous Na2SO4. The solvent was removed under
reduced pressure, and the product was isolated by column SiO2
chromatography: dry-flash, 2  7 mL hexane, 2  7 mL EtOAc:
hexane (9:1), 2  7 mL EtOAc, 10  7 mL EtOAc:MeOH (9:1).
Yield 86.4 mg (77%). Colorless foam softness at 86-89 °C. [R]20D
) +39.13 (c ) 1.61, CH2Cl2). IR (film): 3531w, 3413w, 2951s,
2870m, 1733s, 1611w, 1581s, 1536w, 1446m, 1376s, 1333w, 1248s,
1200w, 1172w, 1146w, 1101m, 1024m, 967w, 940w, 850w, 810w,
768w, cm-1. 1H NMR (200 MHz, CDCl3): 8.54 (d, J ) 5.4,
H-C(2′)), 7.97 (d, J ) 2.2, H-C(8′)), 7.66 (d, J ) 9.2, H-C(5′)),
7.38 (dd, J ) 2.2, J ) 8.9, H-C(6′)), 6.43 (d, J ) 5.4, H-C(3′)),
5.46 (bs, H-N), 5.08 (bs, H-C(12)), 4.95-4.85 (m, H-C(7)), 3.8-
3.9 (m, ArNH-CH2-CH2-O-), 3.66 (s, CH3O2C), 3.55-3.40 (m,
ArNH-CH2-CH2-O-), 3.30-3.12 (m, Hâ-C(3)), 2.10 (s, CH3-
COO-), 2.04 (s, CH3COO-), 0.92 (s, H3C-C(10)), 0.80 (d, J )
5.8, H3C-C(20)), 0.73 (s, H3C-C(13)). 13C NMR (50 Hz,
CDCl3): 174.54, 170.64, 170.51, 151.92, 149.74, 148.99, 134.95,
128.78, 125.43, 120.79, 117.26, 99.29, 79.77, 75.4, 70.77, 65.66,
51.47, 47.29, 45.01, 43.32, 42.9, 41.08, 37.69, 35.58, 34.76, 34.58,
31.34, 30.79, 30.68, 28.9, 27.46, 27.09, 25.51, 22.72, 22.56, 21.58,
21.41, 17.41, 12.15. MS-CI (m/z (%)): 712 [M + H)+, (100)], 688
(5), 651 (10), 591 (5), 477 (2), 370 (3), 317 (2), 279 (2), 192 (3).
N-(Methyl 7r,12r-diacetoxy-5â-cholan-24-oate,3r-yloxy)-
ethyl-N′-(7-chloroquinolin-4-yl)-ethane-1,2-diamine (11). A sus-
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pension of crude 15 (Scheme 1) (203 mg, 0.37 mmol) and 6 (189
mg, 0.85 mmol) was stirred for 30 min at room temperature, and
NaBH(OAc)3 (180.4 mg, 0.85 mmol) was then added in a single
portion. Stirring was continued overnight, solvent was removed,
and the product was isolated by column chromatography on SiO2:
dry-flash, eluent EtOAc/MeOH/NH3 conc. (36:1:1). Yield 120 mg
(43% from 14 (Scheme 1)), colorless solid. [R]20D ) +38.56 (c )
1.53, CH2Cl2). IR (KBr): 3310w, 3057w, 2941m, 2868m, 1733s,
1674w, 1612w, 1581s, 1539w, 1450m, 1375m, 1333w, 1248s,
1147w, 1081w, 1024m, 967w, 880w, 851w, 812w, 769w cm-1.
1H NMR (200 MHz, CDCl3): 8.50 (d, J ) 5.4, H-C(2′)), 7.94 (d,
J ) 2.2, H-C(8′)), 7.76 (d, J ) 9.2, H-C(5′)), 7.37 (dd, J ) 2.2,
J ) 8.8, H-C(6′)), 6.38 (d, J ) 5.4, H-C(3′)), 6.02 (bs, H-N),
5.06 (bs, H-C(12)), 4.95-4.85 (m, H-C(7)), 3.70-3.5 (m,
CH3O2C and ArNH-CH2-CH2-NH-), 3.40-3.30 (m, NH-
CH2-CH2-O), 3.20-3.00 (m, H-C(3) and ArNH-CH2-CH2-
NH-), 2.90-2.80 (m, NH-CH2-CH2-O), 2.08 (s, CH3COO-),
2.04 (s, CH3COO-), 0.90 (s, H3C-C(10)), 0.79 (d, J ) 6.0, H3C-
C(20)), 0.72 (s, H3C-C(13)). 13C NMR (50 Hz, CDCl3): 174.56,
170.71, 170.62, 151.87, 149.94, 148.88, 134.84, 128.45, 125.21,
121.43, 117.28, 99.07, 79.93, 75.4, 70.77, 67.53, 51.47, 48.83,
47.23, 44.99, 43.35, 41.92, 41.09, 37.65, 35.54, 34.8, 34.58, 34.49,
31.34, 30.77, 30.66, 28.97, 27.42, 27.08, 25.55, 22.56, 21.61, 21.41,
17.37, 12.13. MS-EI (m/z (%)): 755 [M + H)+, (20)], 720 (4),
696 (5), 550 (5), 448 (5), 388 (10), 372 (5), 265 (25), 249 (20),
233 (15), 223 (75), 204 (15), 194 (10), 180 (100), 165 (5), 145 (5).
Methyl 3r-(2-Propenyloxy),7r,12r-diacetoxy-5â-cholan-24-
oate (14). Methyl 3R-hydroxy-7R,12R-diacetoxy-5â-cholan-24-
oate51,52 (13) (1 g, 2 mmol) and allyl bromide (25 mL; 296 mmol))
were dissolved in N-methyl pyrrolidin-2-one (NMP; 6 mL), and
diisopropylethylamine (DIEA; 1.4 mL, 8 mmol) was added. The
mixture was stirred for 24 h at 80 °C, and excess of allyl bromide
was removed in vacuo. Crude product was purified by column
chromatography on SiO2: dry-flash and Lobar B LichroPrep, eluent
heptane/EtOAc (8/2). Yield 845 mg (78%) as colorless solid. [R]20D
) +52.07 (c ) 1.21, CH2Cl2). IR (film): 2947s, 2870s, 1736s,
1441m, 1377s, 1246s, 1198m, 1170m, 1125m, 1084s, 1024s, 964w,
935w, 858w, 736w cm-1. 1H NMR (200 MHz, CDCl3): 6.05-
5.80 (m, vinyllic H), 5.27 (bd, J ) 17.2, vinyllic H), 5.17 (bd, J )
10.2 Hz), 5.07 (bs, H-C(12)), 4.95-4.85 (m, H-C(7)), 4.01 (bdd,
J ) 1.3, J ) 5.7, CH2O-), 3.66 (s, CH3O2C), 3.25 - 3.05 (m,
H-C(3)), 2.13 (s, CH3COO-), 2.08 (s, CH3COO-), 0.90 (s, H3C-
C(10)), 0.80 (d, J ) 6.4, H3C-C(20)), 0.72 (s, H3C-C(13)). 13C
NMR (50 Hz, CDCl3): 174.56, 170.75, 170.79, 135.37, 116.73,
78.86, 75.38, 70.77, 69.24, 51.47, 47.29, 45.03, 43.37, 41.17, 37.73,
35.6, 34.90, 34.63, 34.54, 31.41, 30.83, 30.72, 28.95, 27.31, 27.11,
25.56, 22.74, 22.58, 21.67, 21.52, 17.43, 12.16. MS-CI (m/z (%)):
547 [M + H)+, (20)], 487 (80), 427 (100), 369 (50), 312 (5), 284
(3), 253 (5), 226 (4), 146 (3), 119 (2).
(Methyl 7r,12r-diacetoxy-5â-cholan-24-oate,3r-yloxy)acetal-
dehyde (15). A solution of allyl ether 14 (Scheme 1) (808.3 mg,
1.48 mmol) in CH2Cl2/MeOH (90 mL, 2:1) was cooled to -78
°C, and oxygen containing 2.5% ozone was bubbled through for 1
h. Excess ozone was removed with Ar, Me2S (5 mL) was added,
and the reaction mixture was stirred for 15 min at -60 °C and for
2 h at room temperature. The mixture was evaporated to dryness,
and the residue was dissolved in CH2Cl2 (15 mL) and purified
through a short SiO2 column using CH2Cl2 (3  20 mL). The
fractions were combined and evaporated to dryness, affording crude
aldehyde 7 (995 mg). This product was used in the next step without
further purification.
2-(Methyl 7r,12r-diacetoxy-5â-cholan-24-oate,3r-yloxy)etha-
nol (16). This compound was quantitatively obtained in several
unsuccessful reductive amination attempts (i.e., 15 f 10) using
NaBH3CN or NaBH(OAc)3. Average yield 63% (from 14). Color-
less solid. [R]20D ) +64.76 (c ) 1.05, CH2Cl2). IR (film): 3455m,
2950m, 2870m, 1735s, 1651w, 1442m, 1379s, 1247s, 1116m,
1069m, 1069m, 1024m, 967w, 939w, 898w, 861w, 612w cm-1.
1H NMR (200 MHz, CDCl3): 5.07 (bs, H-C(12)), 4.92-4.86 (m,
H-C(7)), 3.79 - 3.68 (m, HO-CH2-CH2-O), 3.66 (s, CH3O2C),
3.62-3.54 (m, HO-CH2-CH2-O), 3.24-3.06 (m, H-C(3)), 2.14
(s, CH3COO-), 2.09 (s, CH3COO-), 0.91 (s, H3C-C(10)), 0.80
(d, J ) 5.8, H3C-C(20)), 0.72 (s, H3C-C(13)). 13C NMR (50 Hz,
CDCl3): 174.56, 170.73, 170.66, 79.80, 75.34, 70.72, 69.21, 61.94,
51.46, 47.23, 44.97, 43.32, 41.06, 37.64, 35.51, 34.76, 34.56, 34.49,
31.34, 30.75, 30.64, 28.9, 27.28, 27.08, 25.51, 22.69, 22.54, 21.63,
21.47, 17.37, 12.11. MS-CI (m/z (%)): 551 [M + H)+, (10)], 490
(10), 430 (100), 368 (10), 340 (2), 277 (2), 214 (5), 188 (5), 154
(5), 123 (5).
Methyl 3r-(2-Azidoethoxy),7r,12r-diacetoxy-5â-cholan-24-
oate (17). A solution of alcohol 16 (Scheme 1) (302.5 mg, 0.55
mmol) in dry pyridine (9 mL) was cooled to 0 °C, MsCl (64 íL,
0.83 mmol) was added, and the resulting mixture was stirred for 1
h at 0 °C. The reaction mixture was diluted with EtOAc, layers
were separated, and the organic layer was washed with dilute HCl.
The organic layer was washed with brine, and dried over anhydrous
Na2SO4. Solvent was removed under reduced pressure, and the
residual oil was dissolved in DMF (9 mL), followed by the addition
of NaN3 (357.3, 5.5 mmol). The mixture was stirred for 24 h at 50
°C, then it was cooled to room temperature, diluted with EtOAc,
and isolated by SiO2 column chromatography: dry-flash, eluent
hexane/EtOAc ) 8:2. Yield 277 mg (88%), mp ) 101-102 °C
(ether/hexane). [R]20D ) +54.17 (c ) 1.44, CH2Cl2). IR (KBr or
film): 2941s, 2870s, 2103s, 1735s, 1442m, 1376s, 1247s, 1199w,
1116m, 1023m, 968w, 939w, 904w, 736w cm-1. 1H NMR (200
MHz, CDCl3): 5.07 (bs, H-C(12)), 4.94-4.86 (m, H-C(7)), 3.74-
3.60 (m, CH3O2C and N3-CH2-CH2-O), 3.40-3.50 (m, N3-
CH2-CH2-O), 3.24-3.08 (m, H-C(3)), 2.12 (s, CH3COO-), 2.08
(s, CH3COO-), 0.91 (s, H3C-C(10)), 0.81 (d, J ) 6.2, H3C-
C(20)), 0.72 (s, H3C-C(13)). 13C NMR (50 Hz, CDCl3): 174.56,
170.75, 79.84, 75.32, 70.72, 66.99, 51.47, 50.85, 47.27, 44.99, 43.3,
41.04, 37.71, 35.42, 34.78, 34.52, 31.32, 30.79, 30.68, 28.86, 27.18,
27.09, 25.47, 22.72, 22.52, 21.54, 21.41, 17.41, 12.13. MS-EI (m/z
(%)): 575 [M + H)+, (10)], 551 (2), 488 (25), 455 (25), 428 (20),
369 (75), 253 (50), 228 (10), 200 (25), 157 (30), 133 (25), 72 (50),
43 (100).
2-(Methyl 7r,12r-diacetoxy-5â-cholan-24-oate,3r-yloxy)etha-
namine (18). Azide 17 (Scheme 1) (134 mg, 0.24 mmol) and PPh3
(72.4 mg, 0.28 mol) were dissolved in THF (4 mL) followed by
the addition of H2O (4.97 íL). The mixture was stirred for 24 h at
50 °C, the solvent was removed under reduced pressure, and product
was isolated by SiO2 column chromatography: dry-flash, 2  10
mL EtOAc, 8  10 mL EtOAc:MeOH:NH3 conc. (18:1:1), 8  10
mL EtOAc:MeOH:NH3 conc. (18:1:1). Yield 100.3 mg (81%).
Colorless foam softness at 71-79 °C. [R]20D ) +56.13 (c ) 1.55,
CH2Cl2). IR (film): 3513w, 3383w, 2951s, 2869m, 1734s, 1442w,
1377m, 1248s, 1199w, 1101m, 1024m, 966w, 939w, 900w, 859w,
736w, 700w cm-1. 1H NMR (200 MHz, CDCl3): 5.07 (bs,
H-C(12)), 4.92-4.84 (m, H-C(7)), 3.66 (s, CH3O2C), 3.56-3.42
(m, H2N-CH2-CH2-O), 3.18-3.00 (m, H-C(3)), 2.90-2.80 (m,
H2N-CH2-CH2-O), 2.13 (s, CH3COO-), 2.08 (s, CH3COO-),
0.90 (s, H3C-C(10)), 0.80 (d, J ) 6.2, H3C-C(20)), 0.72 (s, H3C-
C(13)). 13C NMR (50 Hz, CDCl3): 174.54, 170.68, 79.66, 75.36,
70.74, 70.41, 51.44, 47.23, 44.97, 43.34, 42.02, 41.11, 37.67, 35.58,
34.85, 34.58, 34.49, 31.35, 30.77, 30.66, 28.92, 27.38, 27.08, 25.53,
22.69, 22.56, 21.61, 21.47, 17.37, 12.11. MS-EI (m/z (%)): 550
[M + H)+, (50)], 490 (10), 458 (10), 412 (5), 387 (5), 353 (10),
314 (10), 253 (50), 213 (10), 173 (25), 145 (25), 95 (75), 46 (100).
BoNT/A LC Metalloprotease Activity. The assay to determine
BoNT/A LC metalloprotease activity was performed as previously
described.34,53-55 Percent inhibition measurements were performed
in duplicate, and in all cases standard deviations were less than
(25%. IC50 values for the SMNPIs were calculated from plots of
concentration versus inhibition using seven concentrations each (1
and 2) or nine concentrations each (3 and 4).56 Results are the
averages of duplicate determinations.
Molecular Modeling. Insight II (Accelrys, San Diego, CA) was
used to build and visualize models on a Silicon Graphics Octane
2. Energy refinements were carried out with the Discover program
(Accelrys, San Diego, CA) and the CFF91 forcefield (implemented
through Insight II). The HINT (hydropathic interactions) program
(eduSoft, Richmond, VA) (also implemented through Insight II)
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was used to evaluate model quality based on the quantitation of
intra- and intermolecular contacts.57 HINT parameters were set with
the steric term ) Lennard-Jones 6-9 (for CFF91 compatibility);
lone pair vector focusing ) 10; and distance dependence atom-
atom interactions ) exp(-1/r).
A dynamic conformer33 taken from a trajectory of PDB ref code
1E1H58 was used for enzyme coordinates. Inhibitors 1-4 were
docked using our hydrophobicity first rule,33 which involves
characterizing inhibitor components on the basis of their hydro-
phobicity and polarity.33 Identifying complementary binding sur-
faces for the most hydrophobic components of the inhibitor is
prioritized, followed by the identification of complementary contacts
for polar components. This results in a minimization of unfavorable
intermolecular contacts (hydrophobic-polar, base-base, acid-
acid57) and maximizes favorable interactions (hydrophobic-
hydrophobic, hydrogen bonds, and acid-base57).
Translational, rotational, and torsional adjustments were per-
formed when docking the inhibitors, while, at the same time,
torsional adjustments to enzyme residue side chains (within defined
limits of rotamer libraries) were also examined. A van der Waals
bump of 0.25 Å was used to remove unacceptably close atom-
atom contacts. A described tethered minimization strategy was used
during model refinement.31-33,57,59,60 The strategy involved the
application of 2000 kcal/mol per Å2 of force that was stepped off
the inhibitor-enzyme model in 100 kcal/mol decrements via
minimization with conjugate gradients (until the norm of the
gradient was 0.001 kcal/Å). This process was repeated until all
external force was removed. Following, inter- and intramolecular
analyses of the docked inhibitor were again examined using the
HINT program,57 and unfavorable interactions were removed using
rounds of manual adjustments (translational, rotational, and tor-
sional) and tethered minimizations. Cycles of HINT analyses,
manual adjustments, and tethered energy minimizations were
performed until biochemically reasonable binding models were
obtained.
The program Catalyst 4.7 (Accelrys, San Diego, CA) was used
to map pharmacophore components to inhibitors. Figures 2-4 were
generated using Insight II; Figure 1 was generated using Catalyst
4.7.
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